Pfizer Inc. (PFE) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Pfizer’s revenue went from $52.8B in fiscal 2016 to $62.6B in fiscal 2025, growth of about 1.9% a year.
Net income in fiscal 2025 was $7.8B, a net margin of 12.4%; the best year in this period was 2022 with $31.4B.
Over the twelve months to September 27, 2026, revenue was $63.6B and net income $4.0B.
Free cash flow was $9.1B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 7% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.6B | $62.6B | $63.6B | $59.6B | $101.2B | $81.3B | $41.7B | $40.9B | $40.8B | $52.5B | $52.8B |
| Gross profit | $46.7B | $46.5B | $45.8B | $34.6B | $66.8B | $50.5B | $33.2B | $32.9B | $31.8B | $41.3B | $40.5B |
| Operating income | $7.0B | $10.2B | $11.1B | $3.3B | $36.0B | $25.6B | $8.5B | $12.9B | $4.9B | $13.6B | $9.5B |
| Net income | $4.0B | $7.8B | $8.0B | $2.1B | $31.4B | $22.0B | $9.2B | $16.0B | $11.2B | $21.3B | $7.2B |
| EPS (diluted) | $0.70 | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | $3.52 | $1.17 |
| R&D | $11.5B | $10.4B | $10.8B | $10.7B | $11.4B | $10.4B | $8.7B | $8.4B | $7.8B | $7.7B | $7.9B |
| Revenue growth | — | −1.7% | +6.8% | −41.1% | +24.5% | +95.2% | +1.8% | +0.2% | −22.3% | −0.5% | +8.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.2B | $11.7B | $12.7B | $8.7B | $29.3B | $32.6B | $14.4B | $12.6B | $15.8B | $16.8B | $16.2B |
| Capital spending | -$2.4B | -$2.6B | -$2.9B | -$3.9B | -$3.2B | -$2.7B | -$2.2B | -$2.0B | -$2.0B | -$2.0B | -$1.8B |
| Free cash flow | $11.8B | $9.1B | $9.8B | $4.8B | $26.0B | $29.9B | $12.2B | $10.5B | $13.8B | $14.8B | $14.4B |
| Dividends paid | $9.8B | $9.8B | $9.5B | $9.2B | $9.0B | $8.7B | $8.4B | $8.0B | $8.0B | $7.7B | $7.3B |
| Buybacks | — | — | $0 | $0 | $2.0B | $0 | $0 | $8.9B | $12.2B | $5.0B | $5.0B |
| Stock-based pay | $1.1B | $799M | $877M | $525M | $872M | $1.2B | $755M | $687M | $923M | $840M | $691M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $10.3B | $11.9B | $7.3B | $19.2B | $24.0B | $11.5B | $9.6B | $18.8B | $20.0B | $17.9B |
| Debt | — | $67.3B | $63.8B | $66.9B | $38.7B | $40.8B | $40.6B | $38.7B | $37.7B | $37.1B | $35.6B |
| Equity | — | $86.5B | $88.2B | $89.0B | $95.7B | $77.2B | $63.2B | $63.1B | $63.4B | $71.3B | $59.5B |
| Total assets | — | $208.2B | $213.4B | $226.5B | $197.2B | $181.5B | $154.2B | $167.6B | $159.4B | $171.8B | $171.6B |
| Shares (diluted) | 5.75B | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B | 5.67B | 5.98B | 6.06B | 6.16B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 73.4% | 74.3% | 71.9% | 58.1% | 66.0% | 62.1% | 79.6% | 80.3% | 78.0% | 78.6% | 76.7% |
| Operating margin | 11.0% | 16.3% | 17.5% | 5.5% | 35.5% | 31.5% | 20.4% | 31.5% | 12.0% | 25.8% | 18.1% |
| Net margin | 6.3% | 12.4% | 12.6% | 3.6% | 31.0% | 27.0% | 22.0% | 39.2% | 27.3% | 40.6% | 13.7% |
| FCF margin | 18.5% | 14.5% | 15.5% | 8.1% | 25.7% | 36.7% | 29.2% | 25.8% | 33.9% | 28.2% | 27.2% |
| ROIC | — | 5.2% | 5.8% | 1.7% | 24.2% | 20.1% | 7.7% | 12.0% | 3.8% | 9.9% | 8.7% |
| ROE | — | 9.0% | 9.1% | 2.4% | 32.8% | 28.5% | 14.5% | 25.4% | 17.6% | 29.9% | 12.1% |
Frequently asked questions
What is Pfizer’s annual revenue?
$62.6B in fiscal 2025 and $63.6B over the twelve months to September 27, 2026.
How much profit does Pfizer make?
Net income was $7.8B in fiscal 2025 (net margin 12.4%).
Is Pfizer’s revenue growing?
No: revenue fell 1.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.